RVNC - Revance Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.91
-0.41 (-1.84%)
As of 1:38PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close22.32
Open22.40
Bid22.20 x 1300
Ask22.23 x 800
Day's Range21.80 - 22.50
52 Week Range9.88 - 23.43
Volume295,406
Avg. Volume680,120
Market Cap1.17B
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • Business Wire

    Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive U.S. Distribution Agreement of FDA-Approved Dermal Fillers from TEOXANE SA

    Revance Announces Transformative Aesthetics Portfolio Transaction with Exclusive US Distribution Agreement of FDA-Approved Dermal Fillers from TEOXA

  • Business Wire

    Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference

    Revance to Participate in the 38th Annual J.P. Morgan Healthcare Conference

  • Business Wire

    Revance Provides Corporate Update and Anticipated Milestones for 2020

    Revance Provides Corporate Update and Anticipated Milestones for 2020

  • Business Wire

    Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology

    Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology.

  • Business Wire

    Revance Announces Pricing of Public Offering of Common Stock

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $17.00 per share. Revance has granted the underwriters a 30-day option to purchase up to an aggregate of 975,000 additional shares from the Company. The gross proceeds to the Company from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $110.5 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

  • Business Wire

    Revance Announces Proposed Public Offering of Common Stock

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (“Revance” or the “Company”), today announced a proposed underwritten public offering of its common stock. The Company intends to use the net proceeds received from its offering of common stock to continue to fund the commercialization of DAXI, and the remainder for working capital, research and development and general corporate purposes. The offering will be made only by means of a prospectus supplement.

  • Business Wire

    Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics

    Revance Therapeutics, Inc. (RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the promotion of Dustin Sjuts to the role of Chief Commercial Officer, Aesthetics & Therapeutics, reporting directly to Mark Foley, Revance’s President and Chief Executive Officer. In his new role, Mr. Sjuts will be responsible for all of the company’s commercial operations and launch activities in preparation for DAXI’s anticipated approval in the second half of 2020.

  • Business Wire

    Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines

    Revance Therapeutics, Inc. (RVNC), a biotechnology company pioneering new innovations in neuromodulator products for aesthetic and therapeutic indications, today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines. The submission includes results from the SAKURA Phase 3 trials, which is the largest aesthetic neuromodulator clinical program ever conducted for the treatment of glabellar frown lines.

  • Business Wire

    Revance to Participate in the Stifel 2019 Healthcare Conference

    Revance Therapeutics, Inc. , a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Stifel 2019 Healthcare Conference, in New York, NY.

  • Business Wire

    Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference

    Revance Therapeutics, Inc. , a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Credit Suisse 28th Annual Healthcare Conference, in Scottsdale, AZ.

  • Business Wire

    Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update

    – Conference call and webcast today at 4:30 p.m. ET –

  • Business Wire

    Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia

    Revance Therapeutics, Inc. (RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced it has completed patient enrollment of the company’s pivotal ASPEN-1 Phase 3 clinical trial for its investigational drug candidate DaxibotulinumtoxinA for Injection (DAXI) for the treatment of isolated cervical dystonia (CD), a movement disorder affecting the neck. In total, 301 adult patients were enrolled at 60 sites across the U.S., Canada and Europe.

  • Business Wire

    Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery

    - Results show DaxibotulinumtoxinA for Injection can reduce frown lines for 24 weeks or more -

  • Business Wire

    Revance to Release Third Quarter 2019 Financial Results on Monday, November 4, 2019

    Revance Therapeutics, Inc. (RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will release third quarter 2019 financial results on Monday, November 4, 2019 after the close of market. Revance’s lead product candidate, DaxibotulinumtoxinA for Injection (DAXI), combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components.

  • Business Wire

    Revance to Present Clinical Data Highlighting the Efficacy and Safety of DAXI at the ASDS 2019 Annual Meeting

    Revance Therapeutics, Inc. (RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced three oral presentations at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting to be held in Chicago, October 24-27, 2019. Presented data will showcase Revance’s investigational product DaxibotulinumtoxinA for Injection (DAXI), a novel botulinum toxin type A in clinical development for the treatment of moderate and severe glabellar lines.

  • Business Wire

    Revance Appoints Mark J. Foley as President and CEO, Replacing Dan Browne

    Revance Therapeutics, Inc. (RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the appointment of Mark Foley as President and CEO, replacing Dan Browne, who has stepped down due to a misjudgment in handling an employee matter. Mr. Browne has also resigned from Revance’s Board of Directors.

  • Business Wire

    Revance Earns Great Place to Work® Certification for Second Year

    Revance Therapeutics, Inc. (RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the company is certified as a great workplace by the independent analysts at Great Place to Work® for the second consecutive year.

  • ACCESSWIRE

    Revance Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 5, 2019 / Revance Therapeutics, Inc. (NASDAQ: RVNC ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 5, 2019 at 4:30 ...

  • Business Wire

    Revance Adds Iconic Brand Builder Jill Beraud to Board of Directors

    Revance Therapeutics, Inc. (RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the appointment of Jill Beraud to the company’s Board of Directors. Ms. Beraud brings more than 25 years’ experience building luxury, fashion, beauty, and consumer brands. Ms. Beraud will also chair a newly-formed Revance Brand Strategy Committee focused on establishing the company’s innovative neuromodulator, DaxibotulinumtoxinA for Injection (DAXI), in the minds of consumers.